Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

RA Effectiveness Differs Among Non-TNF Inhibitors

Will Boggs, MD  |  February 5, 2019

NEW YORK (Reuters Health)—Rheumatoid arthritis (RA) outcomes are better with some non-TNF inhibitors than with others, according to French registry data. “Previously, indirect comparisons (meta-analyses) did not show any difference between biologics in terms of effectiveness,” Dr. Jacques-Eric Gottenberg from Strasbourg University Hospital, France, tells Reuters Health by email. “Our direct comparison using observational data…

Filed under:ConditionsRheumatoid Arthritis Tagged with:abataceptnon-TNF inhibitorsRheumatoid Arthritis (RA)rituximabtocilizumab

Canada Approves Erelzi for PsA; Plus FDA Moves to Increase Access to Naloxone

Michele B. Kaufman, PharmD, BCGP  |  February 4, 2019

Health Canada has approved Erelzi, which is biosimilar to Enbrel (etanercept), for treating psoriatic arthritis in adults…

Filed under:AnalgesicsDrug Updates Tagged with:Biologics & BiosimilarsBiosimilarsCanadaetanerceptFDAgeneric drug marketnaloxoneopioidOpioid abusePsoriatic ArthritisU.S. Food and Drug Administration (FDA)

Rheumatoid Arthritis Prevention, Remission & Treatment De-Escalation

Thomas R. Collins  |  January 17, 2019

CHICAGO—With an ever-strengthening foundation beneath the pathophysiology and prediction of rheumatoid arthritis (RA), the field may soon focus more intently on prevention, an expert said at the 2018 ACR/ARHP Annual Meeting. The session also covered the latest in remission targets and therapy de-escalation. RA Prevention Kevin Deane, MD, PhD, associate professor of medicine and principal…

Filed under:ConditionsMeeting ReportsRheumatoid Arthritis Tagged with:2018 ACR/ARHP Annual MeetingpreventionRemissiontreatment de-escalation

The ACR Has Introduced a New Reproductive Health Guideline Draft

Susan Bernstein  |  January 17, 2019

CHICAGO—Reproductive health can be a concern for patients with rheumatic diseases, and practitioners in both disciplines often work closely together. The Reproductive Health in Rheumatic and Musculoskeletal Diseases Guideline, a draft of new clinical recommendations developed by an ACR-convened group for pregnant women, post-menopausal women, lactating women, and women and men trying to conceive or…

Filed under:Clinical Criteria/GuidelinesMeeting Reports Tagged with:deficiency of adenosine deaminase 2 (DADA2)Dr. Chip Chamberspolyarteritis nodosa

Predicting the Unpredictable – Taming the Impulse to Treat

Philip Seo, MD, MHS  |  January 17, 2019

One of my fellows could take better care of his patients if it weren’t for the attendings getting in his way. Or so he tells me. I can hear the howls of protest already. This statement isn’t fair—it is too broad, it doesn’t fairly depict the nuances of the situation or his point of view. First,…

Filed under:ConditionsOpinionRheuminationsSpeak Out Rheum Tagged with:early arthritisVery Early Rheumatoid Arthritis

Case Report: Lymphocytic Vasculitis of the Central Nervous System

Gbemisola Olayemi, MD, Evangeline Scopelitis, MD, & Jerald M. Zakem, MD  |  January 17, 2019

Vasculitis is a group of chronic inflammatory diseases in which the blood vessel is the target of an immune reaction. They can be secondary to connective tissue disease, idiopathic or due to infection, neoplasm or drugs.1 Primary angiitis of the central nervous system (PACNS) is a rare syndrome characterized by inflammatory cell infiltration and necrosis…

Filed under:ConditionsVasculitis Tagged with:central nervous system vasculitiscyclophosphamideMethylprednisolonePrimary Angiitis of the Central Nervous System

Reminder: How to Handle Part D Prior Authorization Requests

From the College  |  January 16, 2019

Note: Although originally posted in January 2018, the advice below remains valid. We see this issue recur each year. As we begin another new year, many rheumatology practices will again receive prior authorization requests from Medicare Part D for all methotrexate prescriptions. When methotrexate is used as a chemotherapeutic drug, it’s covered by Part B,…

Filed under:From the CollegePractice SupportRheumatoid Arthritis Tagged with:Centers for Medicare & Medicaid Services (CMS)Medicare Part DMethotrexatePart D Drugpart D prior authorization requestsRheumatoid Arthritis (RA)

Moderate Liver Enzyme Elevation Found in Patients With & Without Hepatic Steatosis

Carina Stanton  |  January 2, 2019

Limited data are available on liver enzyme elevation in patients with RA, PsA and psoriasis being treated with tofacitinib and methotrexate. But early study findings are shedding light on the nature and risks of liver enzyme levels in these patients…

Filed under:Conditions Tagged with:fatty liver diseasehepatic steatosisliverliver enzyme levelsTofacitinib

Can IL-6 Predict Sarilumab Response?

Michele B. Kaufman, PharmD, BCGP  |  January 2, 2019

Recent post-hoc analyses of two Phase 3 clinical trials show that RA patients with high interleukin 6 levels taking sarilumab experienced improved symptoms and less joint damage than those using other treatments…

Filed under:Drug Updates Tagged with:adalimumabMethotrexatesarilumab

How Advances in Artificial Intelligence May Aid Rheumatology

Richard Quinn  |  December 19, 2018

From digital scribes to predictive pharmacology—as artificial intelligence advances, technology has a lot to offer medicine. What opportunities lie ahead for rheumatologists and their patients?

Filed under:Technology Tagged with:appsartificial intelligenceelectronic health record (EHR)Technology

  • « Previous Page
  • 1
  • …
  • 44
  • 45
  • 46
  • 47
  • 48
  • …
  • 105
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences